Center for Chronic Disease Outcomes Research, Minneapolis VA Health Care System, 1 Veterans Drive, Minneapolis, MN 55417, USA.
Johns Hopkins University School of Medicine, Bayview Medical Center, Nathan Shock Drive, Baltimore, MD 21224, USA.
J Subst Abuse Treat. 2017 Aug;79:46-52. doi: 10.1016/j.jsat.2017.05.013. Epub 2017 May 25.
Veterans Health Administration (VHA) patients with substance use disorder (SUD) diagnoses incur significantly higher overall health care costs compared to the average annual costs of VHA patients. Because SUDs are relapsing/remitting chronic illnesses, it is important to understand how service costs shift over time in relation to active SUD treatment episodes in order to identify strategies which may enhance treatment outcomes and thereby reduce costs. The primary aim of the current study was to examine VHA health care costs derived from VHA administrative data for 330 Veterans during the years prior to and following patient entry into outpatient SUD treatment in two VHA facilities. Secondary aims were to examine the impact on treatment costs of patient diagnosis (alcohol dependence only vs. stimulant dependence) and participation in an abstinence incentive intervention. There was a significant effect of time on health care costs (p<0.001). Average total costs per patient per quarter were $2204 for quarters 1 through 3, increased significantly to $7507 in quarter 4 and $8030 in quarter 5, then decreased significantly to $3969 in quarters 6 through 8. Increases in quarter 4 and 5 were attributable to inpatient costs whereas increases in the quarters following treatment entry were attributable to outpatient costs (quarters 5-8). Overall costs for patients with alcohol dependence only were approximately 30% higher than overall costs for patients whose diagnoses included stimulant dependence, attributable to higher outpatient costs. There was no significant effect of the 8-week incentive intervention on post-treatment entry costs. Overall, entering SUD treatment corresponded to an increase in health care costs in the quarters both immediately preceding and immediately following treatment entry followed by a tapering down of costs through 12month follow-up; however, longer follow-up is needed to inform the stability of this pattern. Additional research will be needed to determine whether efforts to increase access to SUD treatment, identify patients with SUD earlier on in the course of their disorder and integrate SUD treatment services into primary care settings may assist in engaging patients in treatment prior to experiencing a mental or physical health crisis requiring inpatient treatment and thereby reduce health care costs associated with SUD diagnoses.
退伍军人健康管理局(VHA)中患有物质使用障碍(SUD)的患者的整体医疗保健费用明显高于 VHA 患者的平均年度费用。由于 SUD 是反复发作/缓解的慢性疾病,因此了解服务成本如何随着时间的推移与 SUD 治疗发作相关联,以便确定可能增强治疗效果从而降低成本的策略非常重要。本研究的主要目的是检查从 VHA 行政数据中得出的 330 名退伍军人在两个 VHA 设施中接受门诊 SUD 治疗之前和之后的 VHA 医疗保健费用。次要目的是检查患者诊断(仅酒精依赖与兴奋剂依赖)和参加禁欲激励干预对治疗费用的影响。医疗保健费用随时间有显著影响(p<0.001)。每季度每位患者的平均总费用为第 1 至第 3 季度的 2204 美元,第 4 季度显著增加到 7507 美元,第 5 季度增加到 8030 美元,然后第 6 至第 8 季度显著减少到 3969 美元。第 4 季度和第 5 季度的增加归因于住院费用,而治疗后各季度的增加归因于门诊费用(第 5-8 季度)。仅患有酒精依赖的患者的总费用比同时患有兴奋剂依赖的患者的总费用高约 30%,这归因于更高的门诊费用。为期 8 周的激励干预对治疗后费用没有显著影响。总体而言,进入 SUD 治疗与治疗前和治疗后立即增加医疗保健费用相对应,然后在 12 个月的随访期间逐渐减少费用;然而,需要更长的随访时间来告知这种模式的稳定性。需要进一步的研究来确定是否努力增加 SUD 治疗的机会,更早地发现 SUD 患者,并将 SUD 治疗服务整合到初级保健环境中,可能有助于在经历精神或身体健康危机需要住院治疗之前使患者接受治疗,从而降低与 SUD 诊断相关的医疗保健费用。